CAJ | 학술논문

背景与目的Th17细胞是一种重要的辅助性T细胞，其主要分泌IL-17等细胞因子，在感染免疫、自身免疫性疾病和肿瘤免疫中均有重要意义。本研究旨在探讨Th17细胞和IL-17在肺癌脑转移患者外周血中的表达及IL-17在肺癌脑转移患者脑脊液中的表达和意义。方法流式细胞术检测22例肺癌脑转移患者和20名正常对照外周血Th17（CD3+CD4+IL-23R+）细胞的百分率，ELISA方法检测22例肺癌脑转移患者和20名正常对照血浆IL-17水平， ELISA方法检测19例肺癌脑转移患者和16例无脑转移肺癌患者脑脊液IL-17水平。结果肺癌脑转移患者外周血hT17细胞百分率（4.65%±0.72%）明显高于正常对照（2.71%±0.54%, P=0.04）；其中非小细胞肺癌（non-small cell lung cancer, NSCLC）患者和小细胞肺癌（small cell lung cancer, SCLC）患者没有差异。肺癌脑转移患者血浆IL-17水平明显高于正常对照（117.4±16.43 pg/mL和72.55±8.19 pg/mL, P=0.02）；其中NSCLC患者和SCLC患者没有差异。肺癌脑转移患者脑脊液IL-17水平明显高于无脑转移的肺癌患者（73.21±7.52 pg/mL和50.25±8.04 pg/mL, P=0.04）。结论肺癌脑转移患者外周血Th17细胞数量增多，血浆IL-17和脑脊液IL-17水平升高，Th17细胞和IL-17可能参与了肺癌脑转移的发生和发展。
배경여목적Th17세포시일충중요적보조성T세포，기주요분비IL-17등세포인자，재감염면역、자신면역성질병화종류면역중균유중요의의。본연구지재탐토Th17세포화IL-17재폐암뇌전이환자외주혈중적표체급IL-17재폐암뇌전이환자뇌척액중적표체화의의。방법류식세포술검측22례폐암뇌전이환자화20명정상대조외주혈Th17（CD3+CD4+IL-23R+）세포적백분솔，ELISA방법검측22례폐암뇌전이환자화20명정상대조혈장IL-17수평， ELISA방법검측19례폐암뇌전이환자화16례무뇌전이폐암환자뇌척액IL-17수평。결과폐암뇌전이환자외주혈hT17세포백분솔（4.65%±0.72%）명현고우정상대조（2.71%±0.54%, P=0.04）；기중비소세포폐암（non-small cell lung cancer, NSCLC）환자화소세포폐암（small cell lung cancer, SCLC）환자몰유차이。폐암뇌전이환자혈장IL-17수평명현고우정상대조（117.4±16.43 pg/mL화72.55±8.19 pg/mL, P=0.02）；기중NSCLC환자화SCLC환자몰유차이。폐암뇌전이환자뇌척액IL-17수평명현고우무뇌전이적폐암환자（73.21±7.52 pg/mL화50.25±8.04 pg/mL, P=0.04）。결론폐암뇌전이환자외주혈Th17세포수량증다，혈장IL-17화뇌척액IL-17수평승고，Th17세포화IL-17가능삼여료폐암뇌전이적발생화발전。
Background and objective Th17 cells are important T helper cells, which are characterized by their production of IL-17. hT17 cells play an important role in host defense against microbial infections, autoimmune diseases and cancer. hTe aim of this study is to investigate the percentage of hT17 in peripheral blood lymphocyte and the level of IL-17 in serum and cerebrospinal lfuid (CSF) in patients with brain metastases from lung cancer. Methods Twenty-two patients with brain metastases from lung cancer and 20 health controls were analyzed. hTe percentage of hT17 cell was detected with lfow cytometry using CD3+CD4+IL-23R+marker, the level of IL-17 was measured with ELISA method. Results hTe percentage of hT17 cells in patients with brain metastases from lung cancer was 4.65%±0.72%, which was remarkably higher than that in con-trols (2.71%±0.54%, P=0.04). hTere was no signiifcant difference between non-small cell lung cancer (NSCLC) patients and small cell lung cancer (SCLC) patients. Serum IL-17 was remarkably increased in patients with brain metastases from lung can-cer (117.4±16.43 pg/mL vs 72.55±8.19 pg/mL, P=0.02). No signiifcant difference of the serum IL-17 was observed between NSCLC and SCLC patients. hTe level of IL-17 in CSF from patients with brain metastases from lung cancer was signiifcant higher than that from lung cancer patients without brain metastases (73.21±7.52 pg/mL vs 50.25±8.04 pg/mL, P=0.04). Con-clusion hT17 cells and IL-17 increase in patients with brain metastases from lung cancer. It may involve in the pathogenesis of brain metastases from lung cancer.